{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:56:25Z","timestamp":1791597385694,"version":"4.3.4"},"reference-count":121,"publisher":"The Endocrine Society","issue":"9","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Vasomotor symptoms (VMS) including hot flashes are a common toxicity reported by men undergoing androgen deprivation therapy (ADT) and their effective mitigation remains crucial in prostate cancer survivorship. As the understanding of hot flash pathophysiology is refined, novel therapies offer promising benefits to this patient cohort.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Evidence Acquisition<\/jats:title>\n                  <jats:p>The following mini-review outlines the landscape of VMS management in patients with prostate cancer as informed by a literature search using the PubMed and Embase databases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Evidence Synthesis<\/jats:title>\n                  <jats:p>Hormonal therapies appear most effective for ameliorating VMS in men with prostate cancer experiencing bothersome hot flashes. Transdermal estradiol has been well-validated, with recent evidence hinting at its promise as an alternative form of ADT that mitigates VMS. Nonhormonal treatments proven to be efficacious include gabapentin, oxybutynin, and various antidepressants, although their utility can be limited by adverse effects. There is significant interest in novel agents like fezolinetant that target hypothalamic thermoregulatory pathways; however, further validation in this cohort is required. Nonpharmacological options, including cognitive behavior therapy and acupuncture, may also have a role, although further research is needed to clarify the optimal schedule and confirm superiority over placebo.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Clinicians should be prepared to offer evidence-based management options for the detrimental effects of ADT. Proven therapies for VMS, including oxybutynin and antidepressants, may soon be complemented by neurokinin antagonists, which currently boast great efficacy for menopausal hot flashes. Hormonal options like transdermal estrogen are most likely to provide relief but gynecomastia may develop.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgaf302","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T13:43:17Z","timestamp":1747834997000},"page":"2509-2519","source":"Crossref","is-referenced-by-count":7,"title":["A Review of Hot Flash Management in Patients With Prostate Cancer"],"prefix":"10.1210","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5394-682X","authenticated-orcid":false,"given":"Kevin Lawrence","family":"Lin","sequence":"first","affiliation":[{"name":"The Kinghorn Cancer Centre, St Vincent\u2019s Hospital Sydney , Darlinghurst, NSW 2010 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barak","family":"Talmor","sequence":"additional","affiliation":[{"name":"The Kinghorn Cancer Centre, St Vincent\u2019s Hospital Sydney , Darlinghurst, NSW 2010 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7213-900X","authenticated-orcid":false,"given":"Megan","family":"Crumbaker","sequence":"additional","affiliation":[{"name":"The Kinghorn Cancer Centre, St Vincent\u2019s Hospital Sydney , Darlinghurst, NSW 2010 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5159-4580","authenticated-orcid":false,"given":"Anthony Michael","family":"Joshua","sequence":"additional","affiliation":[{"name":"The Kinghorn Cancer Centre, St Vincent\u2019s Hospital Sydney , Darlinghurst, NSW 2010 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"2025081215521853200_dgaf302-B1","volume-title":"Global Cancer Observatory: Cancer Today","author":"Bray","year":"2024"},{"issue":"16","key":"2025081215521853200_dgaf302-B2","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"2025081215521853200_dgaf302-B3","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","article-title":"EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer","volume":"65","author":"Heidenreich","year":"2014","journal-title":"Eur Urol"},{"issue":"1","key":"2025081215521853200_dgaf302-B4","doi-asserted-by":"crossref","first-page":"R23","DOI":"10.1530\/EJE-18-1000","article-title":"MECHANISMS IN ENDOCRINOLOGY: estradiol as a male hormone","volume":"181","author":"Russell","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2025081215521853200_dgaf302-B5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/aja.2011.101","article-title":"Androgen deprivation therapy-associated vasomotor symptoms","volume":"14","author":"Jones","year":"2012","journal-title":"Asian J Androl"},{"issue":"1","key":"2025081215521853200_dgaf302-B6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.maturitas.2009.10.017","article-title":"Managing hot flushes in men after prostate cancer\u2014a systematic review","volume":"65","author":"Frisk","year":"2010","journal-title":"Maturitas"},{"issue":"10","key":"2025081215521853200_dgaf302-B7","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.clon.2017.06.009","article-title":"The relationship between hot flashes and testosterone recovery after 12 months of androgen suppression for men with localised prostate cancer in the ASCENDE-RT trial","volume":"29","author":"Dosani","year":"2017","journal-title":"Clin Oncol"},{"issue":"4","key":"2025081215521853200_dgaf302-B8","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/S0022-5347(17)32530-2","article-title":"Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma","volume":"152","author":"Karling","year":"1994","journal-title":"J Urol"},{"issue":"2","key":"2025081215521853200_dgaf302-B9","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/pcan.2011.11","article-title":"Hot flushes in prostatic cancer patients during androgen-deprivation therapy with monthly dose of degarelix or leuprolide","volume":"14","author":"Iversen","year":"2011","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"2025081215521853200_dgaf302-B10","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/cen.13249","article-title":"Quality of life decrements in men with prostate cancer undergoing androgen deprivation therapy","volume":"86","author":"Cheung","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"9","key":"2025081215521853200_dgaf302-B11","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/j.1442-2042.2004.00896.x","article-title":"Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy","volume":"11","author":"Nishiyama","year":"2004","journal-title":"Int J Urol"},{"issue":"3","key":"2025081215521853200_dgaf302-B12","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/cncr.31024","article-title":"Sleep disturbance in men receiving androgen deprivation therapy for prostate cancer: the role of hot flashes and nocturia","volume":"124","author":"Gonzalez","year":"2018","journal-title":"Cancer"},{"issue":"2","key":"2025081215521853200_dgaf302-B13","doi-asserted-by":"crossref","first-page":"e000040","DOI":"10.1136\/esmoopen-2016-000040","article-title":"International survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries","volume":"1","author":"Liede","year":"2016","journal-title":"ESMO Open"},{"issue":"3","key":"2025081215521853200_dgaf302-B14","first-page":"128","article-title":"Gabapentin for the management of hot flashes in prostate cancer survivors: a longitudinal continuation study\u2014NCCTG trial N00CB","volume":"8","author":"Moraska","year":"2010","journal-title":"J Support Oncol"},{"issue":"48","key":"2025081215521853200_dgaf302-B15","doi-asserted-by":"crossref","first-page":"19846","DOI":"10.1073\/pnas.1211517109","article-title":"Role for kisspeptin\/neurokinin B\/dynorphin (KNDy) neurons in cutaneous vasodilatation and the estrogen modulation of body temperature","volume":"109","author":"Mittelman-Smith","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"2025081215521853200_dgaf302-B16","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1210\/en.2007-0961","article-title":"Kisspeptin neurons in the arcuate nucleus of the ewe express both dynorphin A and neurokinin B","volume":"148","author":"Goodman","year":"2007","journal-title":"Endocrinology"},{"issue":"7","key":"2025081215521853200_dgaf302-B17","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1210\/jc.2007-0553","article-title":"Hypertrophy and increased kisspeptin gene expression in the hypothalamic infundibular nucleus of postmenopausal women and ovariectomized monkeys","volume":"92","author":"Rometo","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"19","key":"2025081215521853200_dgaf302-B18","doi-asserted-by":"crossref","first-page":"8848","DOI":"10.1073\/pnas.0913358107","article-title":"A thermosensory pathway mediating heat-defense responses","volume":"107","author":"Nakamura","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2025081215521853200_dgaf302-B19","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1210\/en.2011-0164","article-title":"Projections of arcuate nucleus and rostral periventricular kisspeptin neurons in the adult female mouse brain","volume":"152","author":"Yeo","year":"2011","journal-title":"Endocrinology"},{"issue":"1","key":"2025081215521853200_dgaf302-B20","doi-asserted-by":"crossref","first-page":"E19","DOI":"10.1210\/jc.2012-2880","article-title":"Effects of neurokinin B administration on reproductive hormone secretion in healthy men and women","volume":"99","author":"Jayasena","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025081215521853200_dgaf302-B21","doi-asserted-by":"crossref","first-page":"8466","DOI":"10.1038\/srep08466","article-title":"Neurokinin B administration induces hot flushes in women","volume":"5","author":"Jayasena","year":"2015","journal-title":"Sci Rep"},{"issue":"2","key":"2025081215521853200_dgaf302-B22","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.celrep.2018.06.037","article-title":"A neural circuit underlying the generation of hot flushes","volume":"24","author":"Padilla","year":"2018","journal-title":"Cell Rep"},{"issue":"42","key":"2025081215521853200_dgaf302-B23","doi-asserted-by":"crossref","first-page":"13109","DOI":"10.1073\/pnas.1512243112","article-title":"Selective optogenetic activation of arcuate kisspeptin neurons generates pulsatile luteinizing hormone secretion","volume":"112","author":"Han","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"2025081215521853200_dgaf302-B24","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1210\/jc.2016-1612","article-title":"Effects of testosterone and estradiol deficiency on vasomotor symptoms in hypogonadal men","volume":"101","author":"Taylor","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2025081215521853200_dgaf302-B25","first-page":"35","volume-title":"Endotext","author":"Rochira","year":"2000"},{"issue":"5","key":"2025081215521853200_dgaf302-B26","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1530\/EJE-22-0318","article-title":"Effects of oestradiol treatment on hot flushes in men undergoing androgen deprivation therapy for prostate cancer: a randomised placebo-controlled trial","volume":"187","author":"Russell","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2025081215521853200_dgaf302-B27","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3747\/co.v17i1.473","article-title":"Management of hot flashes in women with breast cancer","volume":"17","author":"Kligman","year":"2010","journal-title":"Curr Oncol"},{"issue":"2","key":"2025081215521853200_dgaf302-B28","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1055\/s-2005-869479","article-title":"Pathophysiology and treatment of menopausal hot flashes","volume":"23","author":"Freedman","year":"2005","journal-title":"Semin Reprod Med"},{"issue":"1","key":"2025081215521853200_dgaf302-B29","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.maturitas.2014.01.007","article-title":"Cognitive behaviour therapy for menopausal symptoms following breast cancer treatment: who benefits and how does it work?","volume":"78","author":"Chilcot","year":"2014","journal-title":"Maturitas"},{"issue":"1","key":"2025081215521853200_dgaf302-B30","first-page":"1","article-title":"Clinical hypnosis and cognitive behavioral therapy for hot flashes: a scoping review","volume":"6","author":"Mu\u00f1iz","year":"2025","journal-title":"Womens Health Rep"},{"issue":"9","key":"2025081215521853200_dgaf302-B31","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/pon.3794","article-title":"A randomised controlled trial of a brief cognitive behavioural intervention for men who have hot flushes following prostate cancer treatment (MANCAN)","volume":"24","author":"Stefanopoulou","year":"2015","journal-title":"Psychooncology"},{"issue":"17_suppl","key":"2025081215521853200_dgaf302-B32","doi-asserted-by":"publisher","first-page":"LBA5004","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA5004","article-title":"MANCAN2: a multicentre randomised controlled trial of self-help cognitive behavioural therapy (CBT) to manage hot flush and night sweats (HFNS) symptoms in patients with prostate cancer receiving androgen deprivation therapy (ADT)","volume":"42","author":"Morgan","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025081215521853200_dgaf302-B33","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1017\/S0033291721005407","article-title":"Efficacy of cognitive therapy and behavior therapy for menopausal symptoms: a systematic review and meta-analysis","volume":"52","author":"Ye","year":"2022","journal-title":"Psychol Med"},{"issue":"1","key":"2025081215521853200_dgaf302-B34","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/GME.0000000000001651","article-title":"Acupuncture ameliorated vasomotor symptoms during menopausal transition: single-blind, placebo-controlled, randomized trial to test treatment efficacy","volume":"28","author":"Soares","year":"2021","journal-title":"Menopause"},{"issue":"2","key":"2025081215521853200_dgaf302-B35","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/GME.0000000000000735","article-title":"Trajectories of response to acupuncture for menopausal vasomotor symptoms: the acupuncture in menopause (AIM) study","volume":"24","author":"Avis","year":"2017","journal-title":"Menopause"},{"issue":"1","key":"2025081215521853200_dgaf302-B36","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12906-021-03208-2","article-title":"Factors associated with a clinically relevant reduction in menopausal symptoms of a standardized acupuncture approach for women with bothersome menopausal symptoms","volume":"21","author":"Waldorff","year":"2021","journal-title":"BMC Complement Med Ther"},{"issue":"7","key":"2025081215521853200_dgaf302-B37","first-page":"763","article-title":"Acupuncture for treating hot flushes in men with prostate cancer: a systematic review","volume":"17","author":"Lee","year":"2009","journal-title":"Support Care Cancer"},{"issue":"1","key":"2025081215521853200_dgaf302-B38","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.eururo.2008.02.002","article-title":"Two modes of acupuncture as a treatment for hot flushes in men with prostate cancer\u2014a prospective multicenter study with long-term follow-up","volume":"55","author":"Frisk","year":"2009","journal-title":"Eur Urol"},{"issue":"5","key":"2025081215521853200_dgaf302-B39","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.urology.2010.03.033","article-title":"Acupuncture for hot flashes in patients with prostate cancer","volume":"76","author":"Beer","year":"2010","journal-title":"Urology"},{"issue":"9","key":"2025081215521853200_dgaf302-B40","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1001\/archinte.161.9.1161","article-title":"A review of the evidence for the use of phytoestrogens as a replacement for traditional estrogen replacement therapy","volume":"161","author":"Glazier","year":"2001","journal-title":"Arch Intern Med"},{"issue":"5","key":"2025081215521853200_dgaf302-B41","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.juro.2009.07.030","article-title":"Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy","volume":"182","author":"Sharma","year":"2009","journal-title":"J Urol"},{"issue":"32","key":"2025081215521853200_dgaf302-B42","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1200\/JCO.2012.48.1432","article-title":"Randomized trial to assess the impact of venlafaxine and soy protein on hot flashes and quality of life in men with prostate cancer","volume":"31","author":"Vitolins","year":"2013","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025081215521853200_dgaf302-B43","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/sleep\/17.6.497","article-title":"The thermoregulatory effects of menopausal hot flashes on sleep","volume":"17","author":"Woodward","year":"1994","journal-title":"Sleep"},{"issue":"13","key":"2025081215521853200_dgaf302-B44","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2013.278040","article-title":"Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's health initiative randomized trials","volume":"310","author":"Manson","year":"2013","journal-title":"JAMA"},{"key":"2025081215521853200_dgaf302-B45","first-page":"165","article-title":"Hormone therapy for prostate cancer: results of the veterans administration cooperative urological research group studies","volume":"7","author":"Byar","year":"1988","journal-title":"NCI Monogr"},{"key":"2025081215521853200_dgaf302-B46","doi-asserted-by":"crossref","first-page":"S1258","DOI":"10.1016\/j.annonc.2024.08.2312","article-title":"LBA69 prostate cancer efficacy results from a randomised phase III evaluation of transdermal oestradiol (tE2) versus luteinising hormone releasing hormone agonists (LHRHa) for androgen suppression in non-metastatic (M0) prostate cancer","volume":"35","author":"Langley","year":"2024","journal-title":"Ann Oncol"},{"issue":"4","key":"2025081215521853200_dgaf302-B47","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/pros.2990140410","article-title":"Estrogen therapy and liver function\u2014metabolic effects of oral and parenteral administration","volume":"14","author":"von Schoultz","year":"1989","journal-title":"Prostate"},{"issue":"1","key":"2025081215521853200_dgaf302-B48","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.clon.2023.10.054","article-title":"A repurposing programme evaluating transdermal oestradiol patches for the treatment of prostate cancer within the PATCH and STAMPEDE trials: current results and adapting trial design","volume":"36","author":"Gilbert","year":"2024","journal-title":"Clin Oncol"},{"issue":"1","key":"2025081215521853200_dgaf302-B49","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0090-4295(99)00370-2","article-title":"Transdermal estrogen in the treatment of hot flushes in men with prostate cancer","volume":"55","author":"Gerber","year":"2000","journal-title":"Urology"},{"issue":"5_suppl","key":"2025081215521853200_dgaf302-B50","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1200\/JCO.2025.43.5_suppl.21","article-title":"Transdermal oestradiol (tE2) patches as androgen deprivation therapy (ADT): efficacy and safety of combining with androgen receptor pathway inhibitors (ARPIs) in metastatic (M1) prostate cancer\u2014randomised comparison from the STAMPEDE trial platform","volume":"43","author":"James","year":"2025","journal-title":"J Clin Oncol"},{"key":"2025081215521853200_dgaf302-B51","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.euros.2022.09.006","article-title":"Estetrol prevents hot flushes and improves quality of life in patients with advanced prostate cancer treated with androgen deprivation therapy: the PCombi study","volume":"45","author":"Zimmerman","year":"2022","journal-title":"Eur Urol Open Sci"},{"issue":"2","key":"2025081215521853200_dgaf302-B52","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1470-2045(09)70338-9","article-title":"Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial","volume":"11","author":"Irani","year":"2010","journal-title":"Lancet Oncol"},{"issue":"6","key":"2025081215521853200_dgaf302-B53","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJM199408113310602","article-title":"Megestrol acetate for the prevention of hot flashes","volume":"331","author":"Loprinzi","year":"1994","journal-title":"N Engl J Med"},{"issue":"8363","key":"2025081215521853200_dgaf302-B54","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/S0140-6736(83)91092-9","article-title":"CYPROTERONE ACETATE IN TREATMENT OF POST-ORCHIDECTOMY HOT FLUSHES: double-blind cross-over trial","volume":"322","author":"Eaton","year":"1983","journal-title":"Lancet"},{"issue":"6","key":"2025081215521853200_dgaf302-B55","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/0090-4295(92)90401-H","article-title":"Treatment of castration-induced menopausal symptoms with low dose diethylstilbestrol in men with advanced prostate cancer","volume":"40","author":"Miller","year":"1992","journal-title":"Urology"},{"issue":"4","key":"2025081215521853200_dgaf302-B56","first-page":"243","article-title":"A randomized study on hormone-resistant prostatic cancer: estramustine phosphate versus low dose epirubicin with or without medroxyprogesterone acetate. A Norwegian multicenter study","volume":"24","author":"Tveter","year":"1990","journal-title":"Scand J Urol Nephrol"},{"issue":"3","key":"2025081215521853200_dgaf302-B57","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/00000421-199706000-00021","article-title":"Megestrol acetate in the treatment of hormone refractory prostate cancer","volume":"20","author":"Osborn","year":"1997","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"2025081215521853200_dgaf302-B58","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0094-0143(21)01398-7","article-title":"Use of cyproterone acetate in prostate cancer","volume":"18","author":"Goldenberg","year":"1991","journal-title":"Urol Clin North Am"},{"issue":"8363","key":"2025081215521853200_dgaf302-B59","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/S0140-6736(83)91092-9","article-title":"Cyproterone acetate in treatment of post-orchidectomy hot flushes. Double-blind cross-over trial","volume":"2","author":"Eaton","year":"1983","journal-title":"Lancet"},{"issue":"1","key":"2025081215521853200_dgaf302-B60","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1023\/A:1007164319067","article-title":"\u201cHot flush\u201d, an unpleasant symptom accompanying antiandrogen therapy of prostatic cancer and its treatment by cyproterone acetate","volume":"32","author":"Cerven\u00e1kov","year":"2000","journal-title":"Int Urol Nephrol"},{"issue":"4","key":"2025081215521853200_dgaf302-B61","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/gme.0b013e3181679150","article-title":"Mayo clinic and north central cancer treatment group hot flash studies: a 20-year experience","volume":"15","author":"Loprinzi","year":"2008","journal-title":"Menopause"},{"issue":"5","key":"2025081215521853200_dgaf302-B62","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","article-title":"Adverse effects of androgen deprivation therapy and strategies to mitigate them","volume":"67","author":"Nguyen","year":"2015","journal-title":"Eur Urol"},{"issue":"9214","key":"2025081215521853200_dgaf302-B63","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0140-6736(00)02163-2","article-title":"Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials","volume":"355","year":"2000","journal-title":"Lancet"},{"issue":"1","key":"2025081215521853200_dgaf302-B64","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrurol.2014.345","article-title":"Switching and withdrawing hormonal agents for castration-resistant prostate cancer","volume":"12","author":"Lorente","year":"2015","journal-title":"Nat Rev Urol"},{"issue":"20","key":"2025081215521853200_dgaf302-B65","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.3390\/cancers15205047","article-title":"Castration-resistant prostate cancer: from uncovered resistance mechanisms to current treatments","volume":"15","author":"Le","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2025081215521853200_dgaf302-B66","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/00007611-199904000-00013","article-title":"Progressive prostate cancer associated with use of megestrol acetate administered for control of hot flashes","volume":"92","author":"Sartor","year":"1999","journal-title":"South Med J"},{"issue":"3","key":"2025081215521853200_dgaf302-B67","doi-asserted-by":"crossref","first-page":"1086a","DOI":"10.1200\/JCO.1999.17.3.1086a","article-title":"Prostate-specific antigen decline after withdrawal of low-dose megestrol acetate","volume":"17","author":"Burch","year":"1999","journal-title":"J Clin Oncol"},{"issue":"1 Suppl 1","key":"2025081215521853200_dgaf302-B68","first-page":"36","article-title":"Megestrol acetate used as primary hormonal therapy in stage D prostatic cancer","volume":"12","author":"Bonomi","year":"1985","journal-title":"Semin Oncol"},{"issue":"5","key":"2025081215521853200_dgaf302-B69","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0885-3924(03)00043-5","article-title":"Rapid progression of advanced \u201chormone-resistant\u201d prostate cancer during palliative treatment with progestins for cancer cachexia","volume":"25","author":"Tassinari","year":"2003","journal-title":"J Pain Symptom Manage"},{"issue":"1","key":"2025081215521853200_dgaf302-B70","first-page":"37","article-title":"Therapy of vasomotor syndrome in the treatment of advanced prostatic cancer: apropos of 37 cases","volume":"70","author":"Ronzoni","year":"1998","journal-title":"Arch Ital Urol Androl"},{"issue":"5-6","key":"2025081215521853200_dgaf302-B71","doi-asserted-by":"crossref","first-page":"E458","DOI":"10.5489\/cuaj.1753","article-title":"Hepatic failure induced by cyproterone acetate: a case report and literature review","volume":"8","author":"Kim","year":"2014","journal-title":"Can Urol Assoc J"},{"issue":"1","key":"2025081215521853200_dgaf302-B72","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1634\/theoncologist.2-1-18","article-title":"Tolerability of nonsteroidal antiandrogens in the treatment of advanced prostate cancer","volume":"2","author":"McLeod","year":"1997","journal-title":"Oncologist"},{"issue":"1","key":"2025081215521853200_dgaf302-B73","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/tre.377","article-title":"Managing hot flushes in men receiving androgen deprivation therapy for prostate cancer","volume":"5","author":"Khan","year":"2014","journal-title":"Trends Urol Men\u2019s Health"},{"issue":"3","key":"2025081215521853200_dgaf302-B74","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jama.2010.2016","article-title":"Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial","volume":"305","author":"Freeman","year":"2011","journal-title":"JAMA"},{"issue":"28","key":"2025081215521853200_dgaf302-B75","doi-asserted-by":"crossref","first-page":"6919","DOI":"10.1200\/JCO.2005.10.081","article-title":"Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial","volume":"23","author":"Stearns","year":"2005","journal-title":"J Clin Oncol"},{"issue":"21","key":"2025081215521853200_dgaf302-B76","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1001\/jama.289.21.2827","article-title":"Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial","volume":"289","author":"Stearns","year":"2003","journal-title":"JAMA"},{"issue":"3","key":"2025081215521853200_dgaf302-B77","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s10549-008-0138-7","article-title":"Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a double-blind, randomized cross-over study","volume":"115","author":"Buijs","year":"2009","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"2025081215521853200_dgaf302-B78","first-page":"E86","article-title":"Comparing pharmacologics, natural health products, physical and behavioral interventions for management of hot flashes in patients with breast and prostate cancer: a systematic review with meta-analyses","volume":"47","author":"Hutton","year":"2020","journal-title":"Oncol Nurs Forum"},{"issue":"3","key":"2025081215521853200_dgaf302-B79","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/sj.pcan.4500891","article-title":"Pilot evaluation of selective serotonin reuptake inhibitor antidepressants in hot flash patients under androgen-deprivation therapy for prostate cancer","volume":"9","author":"Naoe","year":"2006","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"2025081215521853200_dgaf302-B80","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/YIC.0000000000000023","article-title":"A comparative review of escitalopram, paroxetine, and sertraline: are they all alike?","volume":"29","author":"Sanchez","year":"2014","journal-title":"Int Clin Psychopharmacol"},{"issue":"10","key":"2025081215521853200_dgaf302-B81","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.4065\/79.10.1247","article-title":"Pilot evaluation of paroxetine for treating hot flashes in men","volume":"79","author":"Loprinzi","year":"2004","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"2025081215521853200_dgaf302-B82","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.urolonc.2020.08.003","article-title":"Androgen receptor inhibitor treatments: cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer","volume":"39","author":"Morgans","year":"2021","journal-title":"Urol Oncol"},{"issue":"9488","key":"2025081215521853200_dgaf302-B83","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/S0140-6736(05)67215-7","article-title":"Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial","volume":"366","author":"Pandya","year":"2005","journal-title":"Lancet"},{"issue":"2","key":"2025081215521853200_dgaf302-B84","first-page":"337","article-title":"Gabapentin\u2019s effects on hot flashes in postmenopausal women: a randomized controlled trial","volume":"101","author":"Guttuso","year":"2003","journal-title":"Obstet Gynecol"},{"issue":"3","key":"2025081215521853200_dgaf302-B85","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1345\/aph.1A139","article-title":"Gabapentin for hot flashes in prostate cancer","volume":"36","author":"Jeffery","year":"2002","journal-title":"Ann Pharmacother"},{"issue":"3","key":"2025081215521853200_dgaf302-B86","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/annonc\/mdn644","article-title":"A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB)","volume":"20","author":"Loprinzi","year":"2009","journal-title":"Ann Oncol"},{"issue":"2","key":"2025081215521853200_dgaf302-B87","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1210\/jc.2014-3421","article-title":"Drugs commonly associated with weight change: a systematic review and meta-analysis","volume":"100","author":"Domecq","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2025081215521853200_dgaf302-B88","doi-asserted-by":"crossref","first-page":"788","DOI":"10.7326\/0003-4819-132-10-200005160-00004","article-title":"Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a university of Rochester cancer center community clinical oncology program study","volume":"132","author":"Pandya","year":"2000","journal-title":"Ann Intern Med"},{"issue":"1","key":"2025081215521853200_dgaf302-B89","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.1994.12.1.155","article-title":"Transdermal clonidine for ameliorating tamoxifen-induced hot flashes","volume":"12","author":"Goldberg","year":"1994","journal-title":"J Clin Oncol"},{"issue":"2","key":"2025081215521853200_dgaf302-B90","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1177\/106002809302700210","article-title":"Use of clonidine to treat hot flashes secondary to leuprolide or goserelin","volume":"27","author":"Bressler","year":"1993","journal-title":"Ann Pharmacother"},{"issue":"4","key":"2025081215521853200_dgaf302-B91","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0022-5347(17)40081-4","article-title":"Treatment of post-orchiectomy hot flashes with transdermal administration of clonidine","volume":"143","author":"Parra","year":"1990","journal-title":"J Urol"},{"issue":"3","key":"2025081215521853200_dgaf302-B92","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S0022-5347(17)35034-6","article-title":"Transdermal clonidine for ameliorating post-orchiectomy hot flashes","volume":"151","author":"Loprinzi","year":"1994","journal-title":"J Urol"},{"key":"2025081215521853200_dgaf302-B93","first-page":"1","volume-title":"StatPearls","author":"Dwyer","year":"2024"},{"issue":"3","key":"2025081215521853200_dgaf302-B94","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/01.gme.0000243574.01441.3e","article-title":"Oxybutynin for refractory hot flashes in cancer patients","volume":"14","author":"Sexton","year":"2007","journal-title":"Menopause"},{"issue":"1","key":"2025081215521853200_dgaf302-B95","doi-asserted-by":"crossref","first-page":"pkz088","DOI":"10.1093\/jncics\/pkz088","article-title":"Oxybutynin vs placebo for hot flashes in women with or without breast cancer: a randomized, double-blind clinical trial (ACCRU SC-1603)","volume":"4","author":"Leon-Ferre","year":"2019","journal-title":"JNCI Cancer Spectr"},{"issue":"11","key":"2025081215521853200_dgaf302-B96","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1097\/GME.0000000000000773","article-title":"Extended-release oxybutynin therapy for vasomotor symptoms in women: a randomized clinical trial","volume":"23","author":"Simon","year":"2016","journal-title":"Menopause"},{"issue":"1","key":"2025081215521853200_dgaf302-B97","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/nau.24827","article-title":"The risk of delirium and falls or fractures with the use of overactive bladder anticholinergic medications","volume":"41","author":"Welk","year":"2022","journal-title":"Neurourol Urodyn"},{"issue":"5","key":"2025081215521853200_dgaf302-B98","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s11934-011-0198-9","article-title":"Antimuscarinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients","volume":"12","author":"Pagoria","year":"2011","journal-title":"Curr Urol Rep"},{"issue":"18","key":"2025081215521853200_dgaf302-B99","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1056\/NEJMc1801992","article-title":"Oxybutynin for hot flashes due to androgen deprivation in men","volume":"378","author":"Smith","year":"2018","journal-title":"N Engl J Med"},{"issue":"17_suppl","key":"2025081215521853200_dgaf302-B100","doi-asserted-by":"crossref","first-page":"LBA12004","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA12004","article-title":"Alliance A222001: a randomized, double-blind, placebo controlled phase II study of oxybutynin versus placebo for the treatment of hot flashes in men receiving androgen deprivation therapy","volume":"42","author":"Stish","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025081215521853200_dgaf302-B101","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/GME.0000000000001510","article-title":"A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause","volume":"27","author":"Fraser","year":"2020","journal-title":"Menopause"},{"issue":"11","key":"2025081215521853200_dgaf302-B102","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1210\/en.2015-1409","article-title":"The NK3 receptor antagonist ESN364 interrupts pulsatile LH secretion and moderates levels of ovarian hormones throughout the menstrual cycle","volume":"156","author":"Fraser","year":"2015","journal-title":"Endocrinology"},{"key":"2025081215521853200_dgaf302-B103","author":"Office of the Commissioner"},{"issue":"10382","key":"2025081215521853200_dgaf302-B104","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S0140-6736(23)00085-5","article-title":"Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study","volume":"401","author":"Lederman","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"2025081215521853200_dgaf302-B105","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1210\/clinem\/dgad058","article-title":"Efficacy and safety of fezolinetant in moderate to severe vasomotor symptoms associated with menopause: a phase 3 RCT","volume":"108","author":"Johnson","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025081215521853200_dgaf302-B106","doi-asserted-by":"crossref","first-page":"3000605241247684","DOI":"10.1177\/03000605241247684","article-title":"Efficacy and safety of fezolinetant for moderate to severe vasomotor symptoms associated with menopause among women in East Asia: a phase 3 randomized study (MOONLIGHT I)","volume":"52","author":"Ruan","year":"2024","journal-title":"J Int Med Res"},{"issue":"4","key":"2025081215521853200_dgaf302-B107","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/AOG.0000000000005114","article-title":"Safety of fezolinetant for vasomotor symptoms associated with menopause: a randomized controlled trial","volume":"141","author":"Neal-Perry","year":"2023","journal-title":"Obstet Gynecol"},{"issue":"1","key":"2025081215521853200_dgaf302-B108","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/GME.0000000000002281","article-title":"Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause","volume":"31","author":"Morga","year":"2024","journal-title":"Menopause"},{"issue":"S1","key":"2025081215521853200_dgaf302-B109","doi-asserted-by":"crossref","first-page":"5732862","DOI":"10.1152\/physiol.2023.38.S1.5732862","article-title":"KNDy innervation of MCH neurons modulates sleep in an estradiol-dependent manner","volume":"38","author":"Beekly","year":"2023","journal-title":"Physiology"},{"issue":"22","key":"2025081215521853200_dgaf302-B110","doi-asserted-by":"crossref","first-page":"6899","DOI":"10.1016\/j.bmcl.2011.07.116","article-title":"Identification of novel NK1\/NK3 dual antagonists for the potential treatment of schizophrenia","volume":"21","author":"Catalani","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"issue":"16","key":"2025081215521853200_dgaf302-B111","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1001\/jama.2024.14618","article-title":"Elinzanetant for the treatment of vasomotor symptoms associated with menopause: OASIS 1 and 2 randomized clinical trials","volume":"332","author":"Pinkerton","year":"2024","journal-title":"JAMA"},{"issue":"5","key":"2025081215521853200_dgaf302-B112","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1210\/endo-128-5-2239","article-title":"Hypertrophy and increased gene expression of neurons containing neurokinin-B and substance-P messenger ribonucleic acids in the hypothalami of postmenopausal women","volume":"128","author":"Rance","year":"1991","journal-title":"Endocrinology"},{"issue":"6","key":"2025081215521853200_dgaf302-B113","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0893-133X(02)00369-X","article-title":"Effects of the neuropeptide substance P on sleep, mood, and neuroendocrine measures in healthy young men","volume":"27","author":"Lieb","year":"2002","journal-title":"Neuropsychopharmacol"},{"key":"2025081215521853200_dgaf302-B114","author":"Astellas Pharma Global Development Inc"},{"key":"2025081215521853200_dgaf302-B115","author":"University of Michigan Rogel Cancer Center"},{"key":"2025081215521853200_dgaf302-B116","author":"Bayer"},{"issue":"2","key":"2025081215521853200_dgaf302-B117","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1056\/NEJMc2412361","article-title":"Neurokinin-3 receptor antagonism for refractory hot flashes in men","volume":"392","author":"Lin","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"2025081215521853200_dgaf302-B118","first-page":"CD002978","article-title":"Oral oestrogen and combined oestrogen\/progestogen therapy versus placebo for hot flushes","volume":"2004","author":"MacLennan","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2025081215521853200_dgaf302-B119","doi-asserted-by":"crossref","first-page":"20090","DOI":"10.1038\/s41598-020-77255-z","article-title":"Open-label placebos for menopausal hot flushes: a randomized controlled trial","volume":"10","author":"Pan","year":"2020","journal-title":"Sci Rep"},{"issue":"23","key":"2025081215521853200_dgaf302-B120","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1200\/JCO.2001.19.23.4280","article-title":"Methodologic lessons learned from hot flash studies","volume":"19","author":"Sloan","year":"2001","journal-title":"J Clin Oncol"},{"issue":"11","key":"2025081215521853200_dgaf302-B121","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1097\/GME.0b013e31828cec53","article-title":"Sternal skin conductance: a reasonable surrogate for hot flash measurement?","volume":"20","author":"Pachman","year":"2013","journal-title":"Menopause"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaf302\/63266104\/dgaf302.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/9\/2509\/63266104\/dgaf302.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/9\/2509\/63266104\/dgaf302.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T19:52:37Z","timestamp":1755028357000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/110\/9\/2509\/8140119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":121,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,5,21]]},"published-print":{"date-parts":[[2025,8,7]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaf302","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,5,21]]}}}